ABLIVA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.162 SEK | -0.61% |
|
+1.50% | -34.01% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 219M 20.1M |
|---|---|---|---|---|---|
| Net income 2024 * | -142M -13.02M | Net income 2025 * | -157M -14.4M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 124M 11.37M | Net cash position 2025 * | 173M 15.87M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.25
x | P/E ratio 2025 * |
-1.09
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.61% | ||
| 1 week | +1.50% | ||
| Current month | -0.12% | ||
| 1 month | +4.79% | ||
| 3 months | -32.36% | ||
| 6 months | -29.72% | ||
| Current year | -34.01% |
1 week
0.16
0.18
1 month
0.140.18
Current year
0.140.27
1 year
0.140.32
3 years
0.140.79
5 years
0.142.68
10 years
0.1482.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Director of Finance/CFO | 57 | 13-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.162 | -0.61% | 417 541 |
| 24-04-25 | 0.163 | +1.88% | 932,598 |
| 24-04-24 | 0.16 | -5.33% | 1,582,808 |
| 24-04-23 | 0.169 | +1.93% | 1,307,990 |
| 24-04-22 | 0.1658 | +3.88% | 2,787,638 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 09:04 am EDT
More quotes
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
2024-05-20
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.01% | 20.09M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| -0.03% | 22.02B | |
| -17.84% | 20.9B | |
| -9.12% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- ABLI Stock
